 SAN DIEGO, Dec. 23, 2020 PRNewswire -- Halozyme Therapeutics, Inc. NASDAQ: HALO today announced that the European Commission has approved Roches Phesgo, a fixed-dose combination of Perjeta pertuzumab and Herceptin trastuzumab with Halozymes ENHANZE technology, administered... 